Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting

Roberto Musso, Elena Santagostino, Albert Faradji, Alfonso Iorio, Jan van der Meer, Jörgen Ingerslev, Thierry Lambert, Monika Maas-Enriquez, Eduard Gorina

Research output: Contribution to journalArticlepeer-review


The safety of full-length sucrose-formulated recombinant factor VIII (rFVIII-FS; Kogenate® FS) for up to 24 months of use was evaluated in a postmarketing observational study in Europe. Long-term safety and efficacy data were available for 212 patients with severe haemophilia A, including 13 previously untreated patients (PUPs) and 12 patients with 1-19 exposure days (EDs). Patients accumulated a mean (± SD) of 187 (121) EDs to rFVIII-FS and received a total of 39,627 infusions, mainly for prophylaxis and for the treatment of 4,283 spontaneous or trauma-related bleeds during an average observation time of 710 (136) days. Of these bleeding episodes, 85.4% were successfully treated with one or two infusions of rFVIII-FS. Haemostasis was also evaluated during 46 minor to major surgical procedures, and the response to infusion was "excellent" or "good" in all cases. FVIII inhibitor formation was observed in six patients (two de novo; four persistent or recurrent).The de novo cases represent 8.0% (2 of 25) of patients who reported 0-19 previous EDs at study entry. Four of the five patients who reported possible drug-related adverse effects developed inhibitors. The results of this observational study demonstrate the efficacy and safety of rFVIII-FS during normal clinical use in the treatment of patients with severe haemophilia A. Furthermore, these findings are consistent with those of previous phase III clinical studies with rFVIII-FS, particularly with regard to its efficacy and low incidence of inhibitor formation.

Original languageEnglish
Pages (from-to)52-58
Number of pages7
JournalThrombosis and Haemostasis
Issue number1
Publication statusPublished - Jan 2008


  • Haemophilia
  • Inhibitors
  • Kogenate
  • Prophylaxis
  • Recombinant factor VIII

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting'. Together they form a unique fingerprint.

Cite this